NCT03457844 - A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

August 30, 2019

Study Completion Date

August 30, 2019

Conditions

Gastroenteropancreatic Neuroendocrine Tumor G3

Interventions

DRUG

Anlotinib

Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Trial Locations (1)

100021

RECRUITING

Yihebali Chi, Beijing